ACADIA PHARMACEUTICALS INC. (ACAD) Total liabilities 2016–2025
ACADIA PHARMACEUTICALS INC. (ACAD) total liabilities at each fiscal year-end, per SEC filings.
$336.8MFY2025 · since FY2016: $42.7M → $336.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $336.8M | -26.0% |
| FY2024 | $455.0M | +43.4% |
| FY2023 | $317.2M | +69.3% |
| FY2022 | $187.4M | +17.7% |
| FY2021 | $159.2M | +2.3% |
| FY2020 | $155.6M | +85.1% |
| FY2019 | $84.0M | +37.5% |
| FY2018 | $61.1M | +24.2% |
| FY2017 | $49.2M | +15.2% |
| FY2016 | $42.7M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More ACAD financial trends
ACAD RevenueACAD Net incomeACAD Net marginACAD Gross profitACAD Gross marginACAD Operating incomeACAD Operating marginACAD Operating cash flowACAD Free cash flowACAD Capital expendituresACAD Return on equityACAD Stock buybacksACAD Dividends paidACAD Total assetsACAD Shareholders’ equityACAD overview →